Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Depression in Parkinson's disease].

Mitsutoshi Yamamoto1

  • 1Department of Neurology, Kagawa Prefectural Central Hospital.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|October 7, 2004
PubMed
Summary

Depression affects 40% of Parkinson's disease (PD) patients, often as a depressive state linked to dopamine pathway impairment, not major depression. Current treatments are limited due to complex neurochemical changes in PD.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rapid Eye Movement Sleep Behavior Disorder-like Symptoms Due to Arousal Responses Associated with Severe Obstructive Sleep Apnea-hypopnea.

Internal medicine (Tokyo, Japan)·2021
Same author

Non-motor symptoms depending on motor severity in Japanese patients with Parkinson's disease: A multicenter cross-sectional study.

Journal of the neurological sciences·2020
Same author

Repeated anti-N-methyl-D-aspartate receptor encephalitis coexisting with anti-myelin oligodendrocyte glycoprotein antibody-associated diseases: A case report.

Multiple sclerosis and related disorders·2019
Same author

Long-Term Selegiline Monotherapy for the Treatment of Early Parkinson Disease.

Clinical neuropharmacology·2019
Same author

Pharmacological treatment of early Parkinson's disease.

Nihon rinsho. Japanese journal of clinical medicine·2018
Same author

A Randomized Double-Blind Placebo-Controlled Phase III Trial of Selegiline Monotherapy for Early Parkinson Disease.

Clinical neuropharmacology·2017

Area of Science:

  • Neuroscience
  • Neurology
  • Psychiatry

Context:

  • Parkinson's disease (PD) frequently involves depressive symptoms, affecting approximately 40% of patients.
  • The prevalence of major depression in PD is comparable to age-matched controls (2.2-7.7%).
  • Depressive states, distinct from major depression, are considered a core feature of PD.

Purpose:

  • To explore the neurochemical underpinnings of depressive states in Parkinson's disease.
  • To differentiate depressive states from major depression within the PD context.
  • To understand the challenges in developing pharmacological treatments for depression in PD.

Summary:

  • Depressive states in Parkinson's disease are primarily associated with the impairment of the mesocortico-frontal dopaminergic pathway.
  • Parkinson's disease involves complex alterations across multiple neurotransmitter systems, including dopamine, serotonin, and noradrenaline.
  • The intricate neurochemical profile of PD complicates the development of effective antidepressant medications.

Impact:

  • Highlights the need for targeted therapeutic strategies for depressive symptoms in Parkinson's disease.
  • Underscores the complex interplay of neurotransmitter systems in PD-related mood disorders.
  • Suggests that current antidepressant drugs may not be sufficient for treating depression in Parkinson's disease due to its unique neurochemical basis.

Related Experiment Videos